CHRS - Coherus BioSciences Inc.

-

$undefined

N/A

(N/A)

Coherus BioSciences Inc. NASDAQ:CHRS Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings to the health care system.

Location: 333 Twin Dolphin Dr Ste 600, California, 94065-1442, US | Website: www.coherus.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

222.3M

Cash

159.2M

Avg Qtr Burn

-13.57M

Short % of Float

27.07%

Insider Ownership

1.39%

Institutional Own.

73.31%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
UDENYCA® ONBODY Details
Cancer, Chemotherapy-induced neutropenia

Approved

Quarterly sales

Approved

Quarterly sales

CIMERLI (CHS-201) (Lucentis biosimilar) Details
Wet age-related macular degeneration , Age-related macular degeneration, Eye disease

Approved

Quarterly sales

Approved

Quarterly sales

UDENYCA® (pegfilgrastim-cbqv) Biosimilar Details
Cancer, Chemotherapy-induced neutropenia

Approved

Quarterly sales

Phase 3

Update

LOQTORZI (Toripalimab) + INO 3112 Details
HPV+ oropharyngeal cancer, Cancer

Phase 3

Initiation

Phase 2

Update

Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) Details
Non-small cell lung carcinoma, Hepatocellular carcinoma, Solid tumor/s

Phase 1/2

Data readout

Casdozokitug (casdozo) Details
Cancer, Non-small cell lung carcinoma

Phase 1/2

Data readout

CHS-114 (SRF114) Details
Solid tumor/s, Cancer

Phase 1

Data readout

CHS-131 Details
Multiple sclerosis, Non-alcoholic steatohepatitis

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued